Introduction
============

In the majority of cases, aniridia is a panophthalmopathy that is characterized by the absence or hypoplasia of the iris and is associated with other ocular anomalies, such as cataract, foveal hypoplasia, corneal opacity (pannus), coloboma, anterior chamber angle (with secondary glaucoma), or optic nerve malformations, mainly hypoplasia (OMIM [106210](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=106210)). Mostly inherited in an autosomal dominant mode, aniridia can have variable expressivity, and about one-third of the patients are sporadic cases. Mutations in the Paired Box gene 6 (*PAX6*) located on chromosome 11p13 \[[@r1]\] have been shown to cause aniridia \[[@r2]\]. *PAX6* encodes a transcription factor essential for the development of the structures and axes of the eye \[[@r3]\]. Knocking out *PAX6* from the mouse genome results in the absence of the eye, the so-called Small eye (Sey) mouse \[[@r4],[@r5]\].

Furthermore, *PAX6* plays a major role in brain development \[[@r6],[@r7]\] where it is expressed in the telencephalon, the diencephalon, the caudal part of the rhombencephalon, the myelencephalon, and the spinal cord \[[@r3],[@r8]\]. The early death of a baby with a compound heterozygous *PAX6* mutation has been reported, and the brain of this child displayed major brain and cytoarchitectonic abnormalities \[[@r9]\]. Brain imaging (magnetic resonance imaging \[MRI\]) performed in patients heterozygous for *PAX6* mutations often reveals various malformations as well. Absence of the brain anterior or posterior commissure, absence of the pineal gland, and a present but reduced in size corpus callosum have all been reported \[[@r10]-[@r14]\]. These anomalies involve the brain interhemispheric fibers and can thus affect the auditory functions that depend on these fibers \[[@r10]\].

Genotype--phenotype correlations have shown that mutations causing premature termination codons are associated with aniridia and missense mutations are related to non-aniridia phenotypes, such as isolated foveal hypoplasia, microphthalmia, and optic nerve defects \[[@r15]\].

The aim of this study was to analyze three families of Egyptian origin, to describe their clinical phenotype, including brain imaging, and to report the results of their molecular screening. We present two novel and one known nonsense mutations associated with brain anomalies.

Methods
=======

This study was approved by the Ethics Committee of the Faculty of Medicine of the University of Alexandria, Egypt, and was conducted in accordance to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each participant or parent. Ten patients with aniridia belonging to three families of Egyptian origin were included in this study as well as six first-degree relatives ([Figure 1](#f1){ref-type="fig"}). The three families were from the Governorate of Alexandria, in northwestern Egypt. All subjects underwent full ophthalmic, general, and neurological examination, respectively, at the Departments of Ophthalmology, Pediatrics and Neurology of the University of Alexandria, Egypt. Special attention was paid to assessing the presence of associated anomalies, such as Wilms' tumor, urogenital anomalies, or mental retardation, in all subjects. We performed a cerebral MRI in each index patient (Patient III-1 of Family 1, IV-3 of Family 2, and I-1 of Family 3; [Table 1](#t1){ref-type="table"}). MRIs were reviewed by two different radiologists. MRI acquisition techniques included conventional T1- and T2-weighted multisection images (5-mm slice) on a GE Signa HDx 1.5Tesla MRI (General Electric Company, Fairfield, CT).

![Pedigrees and mutation sequences of the three Egyptian families with autosomal dominant aniridia. Male and female subjects are represented by squares and circles, respectively, and affected family members have darkened symbols.](mv-v15-2074-f1){#f1}

###### Ocular and cerebral assessment of the ten patients with aniridia.

  **Patient number**   ***PAX6* Mutation**   **Brain MRI findings**   **Age at examination**   **Visual Acuity RE/LE**                                                                       **Corneal pannus**   **Glaucoma**   **Lens status**                                   
  -------------------- --------------------- ------------------------ ------------------------ --------------------------------------------------------------------------------------------- -------------------- -------------- ----------------- ------------------------------- ----------------------------------------------------------------------------------------
  Family 1                                                                                                                                                                                                                                                                         
  II-7                 7                     c.682-686delTGGGC\*      Q57fx17                  NA                                                                                            46y                  0.1/0.15       yes               yes, bilateral trabeculectomy   bilateral aphakia
  III-1                7                     c.682-686delTGGGC\*      Q57fx17                  absent pineal gland, anterior commissure severe hypoplasia                                    19y                  0.05/0.05      no                yes, bilateral trabeculectomy   bilateral anterior polar cataract with peripheral lens opacities, superior dislocation
  III-2                7                     c.682-686delTGGGC\*      Q57fx17                  NA                                                                                            17y                  0.05/0.05      yes               no                              pseudophakic
  III-4                7                     c.682-686delTGGGC\*      Q57fx17                  NA                                                                                            11y                  0.05/0.05      mild              no                              faint cortical opacities, superior dislocation
  Family 2                                                                                                                                                                                                                                                                         
  III-5                8                     g.30586227delC\*         R159fx47                 NA                                                                                            36y                  0.1/0.2        yes               no                              bilateral anterior polar cataract, faint cortical opacities
  III-6                8                     g.30586227delC\*         R159fx47                 NA                                                                                            44y                  HM/LP          severe            yes, uncontrolled               superior dislocation
  IV-1                 8                     g.30586227delC\*         R159fx47                 NA                                                                                            10y                  0.1/0.1        no                no                              bilateral aphakia
  IV-3                 8                     g.30586227delC\*         R159fx47                 absent pineal gland, absent posterior commissure                                              17y                  0.1/0.1        yes               no                              bilateral posterior polar cataract, superior dislocation
  Family 3                                                                                                                                                                                                                                                                         
  I-1                  9                     g.30579567C\>T           R240X                    absent pineal gland, optic chiasma atrophy, almost complete agenesis of the corpus callosum   35y                  0.1/0.1        mild              no                              normal
  II-1                 9                     g.30579567C\>T           R240X                    NA                                                                                            3m                   NA             no                no                              normal

The asterisk indicated a novel mutation, RE: right eye, LE: left eye, NA: not available.

Molecular analyses
------------------

DNA from patients was extracted from peripheral leucocytes, as previously described \[[@r16]\]. Direct bidirectional resequencing of all PCR-amplified coding exons and adjacent junctions was performed with the ABI Dye Terminator, version 1 (Applied Biosystems, Foster City, CA), in a final reaction volume of 10 μl, and electrophoresed on a 3130XL ABI genetic analyzer (Applied Biosystems). Sequences were compared to the reference sequence [NM_000280.3](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=NM_000280.3), using Chromas version 2.23 (Technelysium, Tewantin, Australia). The adenine of the ATG translation start site was set to 1. Primers and annealing temperature for *PAX6* exons are listed in [Table 2](#t2){ref-type="table"}. In short, amplification was performed in a thermal cycler (GeneAmp 9700; Applied Biosystems), in a total volume of 30 μl. Each PCR contained 100 ng genomic DNA, 0.9 nl of each primer, and 15 μl master mix 2× (Qiagen, Hombrechtikon, Switzerland), with or without betaine. PCR reactions were performed as follows: an initial denaturation step was carried out for 10 min followed by 35 cycles of 1 min at 92 °C, 1 min at the specific annealing temperature ([Table 2](#t2){ref-type="table"}), and 1 min at 72 °C. A final extension cycle at 72 °C for 10 min was performed. Identified mutations were evaluated in 96 ethnic-matched controls by denaturing high-performance liquid chromatography (DHPLC) on a WAVE system (Transgenomics, Crewe, UK). Buffer A contained 0.1 M triethylammonium acetate (TEAA; Transgenomics). Buffer B contained 0.1 M TEAA and 25% acetonitrile HPLC grade (Sigma-Aldrich Co., St. Louis, MO). The flow rate was set at 1.5 ml/min, and the Buffer B gradient was increased by 5% per min for 2 min. The optimum temperature was determined by the Wavemaker software (Transgenomic) for each DNA fragment, and a time shift was applied as needed ([Table 2](#t2){ref-type="table"}). Initial Buffer B concentrations and temperatures for each fragment are listed in [Table 2](#t2){ref-type="table"}.

###### List of initial buffer B concentrations and temperatures for each DNA fragment.

  **PCR**   **WAVE**                                                                  
  --------- ----------------------------- ----------------------- ------------ ------ ------
  1         TGTTGCGGAGTGATTAGTGG          TCCTGGGAAGGAGACAGAGA    60 +betain   60.8   57.9
  2         ACACACTTGAGCCATCACCA          CTCCTGCGTGGAAACTTCT     60 +betain   59.3   60.6
  3         GTGGGTGTAATGCTGGGACT          CCCAATCTGTTTCCCCTACA    60 +betain   56     59.7
  4         CCCCAAGAGGTTGAGTGGAT          GTCGCGAGTCCCTGTGTC      60 +betain   61.4   57.1
  5         TGAGGATGCATTGTGGTTGT          GTGGAAGGAGAGGGGAAAGT    60 +betain   59.5   60.8
  6         TTCAGGCAGTGTTTAAGAAAAGTT      ACTCACACATCCGTTGGACA    55           54.3   58.7
  7         TGCAGATGCAAAAGTCCAAG          CTCTGTTCCCCCAGGTACAA    60 +betain   57.4   61
  8         TTTCCACGGTGTATCTGCAA          AAGCCCTGAGAGGAAATGGT    60 +betain   59.6   59.9
  9         ACCTTGGGAATGTTTTGGTG          CACTGAAAAGATGCCCAGAGA   60 +betain   56.7   60.3
  10        AGGTGGGAACCAGTTTGATG          CATGGCAGCAGAGCATTTAG    60 +betain   57.5   58
  11        TTCAGTCTGCTAAATGCTCTGC        TGTGAGGGCTGTGTCTGTTC    60 +betain   59     60
  12        ACCACACCGGGTAATTTGAA          CTCTCAAGGGTGCAGACACA    60 +betain   58.7   58.4
  13        TAGCTCGAGGCCCAATCTTA          TAAACACGCCCTCCCATAAG    60 +betain   58.3   60
  14        TTTCTGAAGGTGCTACTTTTATTTG     AAGTCCATTCCTTCCCCAGT    55           53.5   60.2
  15        AAACTTAAGTGTTTTGAAGTTGTTCAC   CCCAGATTGAAAATGCCAGT    60 +betain   54.3   60.5

Results
=======

Clinical findings
-----------------

Patients clinical features and mutations description are detailed in [Table 1](#t1){ref-type="table"}. All ten affected patients from the three families had bilateral aniridia, with almost complete absence of iris tissue at its base, and bilateral foveal hypoplasia. Pendular nystagmus consecutive to early severely reduced visual acuity was observed in all affected subjects, except patient III-6 of Family 2 ([Figure 1](#f1){ref-type="fig"}) who presented a left exotropia. Corneal vascularization of different degrees was observed in the three families ([Figure 2](#f2){ref-type="fig"}). Lens abnormalities and glaucoma were present in Families 1 and 2 only. In Family 1, the two affected subjects with glaucoma had controlled pressure after bilateral trabeculectomy, whereas patient III-6 of Family 2 had uncontrolled high pressure. Systemic and neurological examinations were normal in all ten affected subjects. In particular, no kidney or urogenital anomalies on ultrasonography, no mental retardation, no cerebellar abnormal signs, and no olfactory or hearing difficulties were observed or reported.

![Slit-lamp photographs. **A**: Right eye of patient II-7 from Family 1. Note the significant, heavy, corneal vascularization sparing the nasal area. The iris base is very thin, almost invisible, a typical feature of aniridia. The patient was aphakic since cataract surgery performed in childhood. Best-corrected visual acuity was 0.1. **B**: Right eye patient III-4 from Family 1 showing heavy corneal vascularization (pannus) and superior dislocation of the lens. Almost no iris residual tissue is visible, as typically seen in aniridia. Note as well the small anterior polar cataract and the associated faint peripheral cortical opacities. **C** and **D**: Right and left eye of patient IV-3 from Family 2. Note the bilateral posterior polar cataract shaped like the petals of a flower and the superior lens dislocation. **E** and **F**: Fundus photographs. Right and left eye of patient IV-1 from Family 2. Foveal hypoplasia is observed with macular pigment epithelium alterations.](mv-v15-2074-f2){#f2}

Cerebral MRI of Patients III-1 of Family 1 showed a severe hypoplasia of the anterior commissure of the brain and an absent pineal gland; the posterior commissure of the brain was normal ([Figure 3A](#f3){ref-type="fig"}). In Patient IV-3 of Family 2, a total absence of both the pineal gland and the posterior commissure of the brain was observed, but the anterior commissure was normal ([Figure 3C](#f3){ref-type="fig"}). Patient I-1 of Family 3 harbored an almost complete agenesis of the corpus callosum with a small amount of remnant tissue localized at the virtual connection between the genu and the body of the corpus callosum ([Figure 4A](#f4){ref-type="fig"}). In the same patient, Probst bundles were identified ([Figure 4C](#f4){ref-type="fig"}). Concomitant ectasia of the ventricles and atrium, hypoplasia of the optic chiasm ([Figure 4C](#f4){ref-type="fig"}), and total absence of the pineal gland were observed as well ([Figure 4C](#f4){ref-type="fig"}). Both anterior and posterior commissures of the brain were normal.

![Axial cerebral T2-weighted magnetic resonance images. **A**: Patient III-1 from Family 1. Dashed arrow: severe hypoplasia of the anterior commissure. Arrow head: normal posterior commissure. Lower arrow: absence of the pineal gland. **B**: Normal magnetic resonance imaging (MRI) images. Dashed arrow: normal anterior commissure. Arrow head: normal posterior commissure. Lower arrow: normal pineal gland. **C**:  Patient IV-3 from Family 2. Dashed arrow: normal anterior commissure. Arrow head: absent posterior commissure. Lower arrow: absent pineal gland.](mv-v15-2074-f3){#f3}

![Coronal cerebral T2-weighted magnetic resonance images. **A**: Patient I-1 from Family 3. Dashed arrow shows severe hypogenesis of the corpus callosum with small amount of remnant tissue localized at the virtual connection between the genu and the body of the corpus callosum; arrow head shows the atrophic optic chiasm. **B**: Normal MRI images. Dashed arrow shows normal corpus callosum and arrow head shows normal optic chiasm. **C**: Patient I-1 from Family 3. Dashed arrow shows lateral callosal bundles of Probst, which are hemispheric connection fibers that did not cross the midline and that are seen in callosal dysgenesis. Superomedial margins of the lateral ventricles are indented by the Probst bundles. Arrow head shows remnants of the corpus callosum. Lower arrow shows normal posterior commissure. **D**: Normal MRI image with dashed arrow pointing normal corpus callosum.](mv-v15-2074-f4){#f4}

Molecular findings
------------------

In Family 1, a c.170-174delTGGGC mutation was identified in exon 7, generating a frameshift and an early termination 17 codons downstream (p.L57fs17). The mutation was present at the heterozygous state in the four affected members of Family 1 and absent in the two unaffected subjects ([Figure 1](#f1){ref-type="fig"}). Family 2 also exhibited an unreported deletion. The deletion of c.475delC in exon 8 generates a frameshift and a new stop codon 47 amino acids downstream (p.R159fs47). This mutation was present in the three affected subjects and absent in the two unaffected individuals ([Figure 1](#f1){ref-type="fig"}). The two mutations were not detected in 96 ethnically matched healthy individuals and have not been previously reported according to the [Human PAX6 Mutation Database](http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6) \[[@r17]\]. In Family 3, the previously described c.718C\>T (p.R240X) nonsense mutation in exon 9 \[[@r2],[@r18],[@r19]\] was detected in the two affected members and not in the unaffected mother ([Figure 1](#f1){ref-type="fig"}).

Discussion
==========

We report three *PAX6* mutations segregating in three families with aniridia originating from the northwestern part of Egypt. Two of the three mutations are novel frameshifting deletions, and one is a previously described nonsense mutation. To our knowledge, this is the first report of aniridia mutations from this part of the world. It is interesting to note that the pathology of the *PAX6-*related genome is far from being fully determined when one considers that only one of the identified mutants was already known. From a clinical point of view, the ten patients of this series harbored common but extensive features of ocular-isolated aniridia associated with the wide spectrum of already described MRI brain malformations. These include absence of the pineal gland and hypogenesis of the corpus callosum and of the anterior or posterior commissure. The interpretation of the observed MRI malformations is limited by the lack of a full assessment of the neurological development; refined examinations, such as electroencephalogram, neurocognitive tests, or sleep study, were not available. Nevertheless, the patients did not harbor major neurodevelopmental delay that could be detected clinically by a senior geneticist and pediatrician.

In a large genotype--phenotype correlation of the *PAX6* Mutation Database, Tzoulaki et al. \[[@r15]\] established that mutations introducing a premature termination codon (PTC) were predominantly associated with aniridia, whereas non-aniridia phenotypes, such as isolated foveal hypoplasia, microphthalmia, and optic nerve defects, were predominantly caused by missense mutations. These authors showed that the second most frequent type of *PAX6* mutations was frameshifting insertions or deletions and missense mutations were the third. In the present series of patients with typical aniridia, the three identified mutations caused a PTC, and two of them were frameshifting deletions, thus confirming the frequent association of PTC and of frameshifting mutations with aniridia \[[@r15]\].

The p.R240X mutation segregating in Family 3 has previously been described \[[@r2],[@r18],[@r19]\] with more than 20 independent records in the *PAX6* Mutation Database \[[@r17]\]. This mutation is a C\>T transition that occurs on a CpG dinucleotide, a structure known for its high mutability \[[@r20]\]. This CpG in exon 9, located in the homeobox coding region, is a mutation hotspot since CpG dinucleotides of the last third of *PAX6* tend to be methylated and thus more inclined to undergo spontaneous deamination of cytosine, resulting in C\>T transition \[[@r21]\]. A sense-strand deamination of CpG in a CGA codon creates a termination codon CTA. It has been proposed that nonsense-mediated decay (NMD), the mechanism responsible for the elimination of mRNAs that contain premature termination codons before the last exon \[[@r22]\], is highly involved in aniridia since the majority of aniridia *PAX6* mutations introduce premature termination codons \[[@r15]\]. Thus, NMD impedes truncated protein formation, and loss-of-function of one allele is responsible for the development of aniridia through haploinsufficiency. This mechanism may explain how different mutations and different putative truncated proteins can induce similar phenotypes. The Family 1 and 2 unreported mutations, p.L57fs17 and p.R159fs47, are both likely to result in haploinsufficiency through NMD.

Hypoplasia of the anterior commissure \[[@r10],[@r12],[@r14]\], of the posterior commissure \[[@r10]\], and of the corpus callosum \[[@r10]-[@r12],[@r14]\] have been reported in heterozygous carriers of *PAX6* mutations. Absence or hypoplasia of the anterior commissure is present in up to one-third of *PAX6* mutation carriers \[[@r10],[@r13]\]. Abnormal anterior MRI anomalies can be associated with subtle neurological deficits, such as olfactory difficulties \[[@r14]\], hearing difficulties \[[@r10]\], and deficits in executive and social cognition \[[@r11]\], or with aniridia only \[[@r12]\]. We did observe anomalies of these three brain structures in our three imaged patients ([Table 1](#t1){ref-type="table"}). Although no brain anomalies can yet be directly related to any specific *PAX6* mutation, we report the third observation of MRI anomalies associated with the p.R240X mutation \[[@r10],[@r14]\]. In contrast with both Sisodiya et al. \[[@r14]\] and Bamiou et al. \[[@r10]\] who reported a hypoplastic anterior commissure but a normal corpus callosum, we observed in Patient I-1 of Family 3 an almost complete agenesis of the corpus callosum with a normal anterior commissure ([Table 1](#t1){ref-type="table"}, [Figure 4C](#f4){ref-type="fig"}). Interestingly, we observed Probst bundles in this patient ([Figure 4C](#f4){ref-type="fig"}), which highlights the severity of the corpus callosum hypogenesis in this case. Indeed, Probst bundles represent fiber tracts that grow caudally along the medial surface of the ipsilateral cerebral hemisphere that would have crossed the midline in the case of normal corpus callosum development \[[@r23]\]; their presence is common in patients with corpus callosum hypogenesis and twice as frequent in patients with corpus callosum agenesis \[[@r24]\].

We hypothesize that a specific mutation can cause brain anomalies but that the brain anomaly can be expressed differently. Being a transcription factor, *PAX6* interacts with several brain developmental genes and transcription factors, such as the Homeobox gene expressed in ES cells, the *Hesx1* gene \[[@r3]\], whose interaction with *PAX6* could be altered by the presence of a mutant protein causing corpus callosum and brain commissure hypogenesis. It has recently been demonstrated in mouse that the transcription factors Empty spiracles homeobox 2, *Emx2* and *Pax6* are essential for cortical regionalization at the beginning of neuronogenesis \[[@r25]\]. From this perspective, one can hypothesize that abnormal interaction between mutated PAX6 protein and a normal EMX2 protein could be responsible for the presence of the interhemispheric brain anomalies. Moreover, the possibility of digenism is not excluded with the presence of an undetected *EMX2* mutation added to the *PAX6* one to result in corpus callosum and commissure dysgenesis. Last, the existence of at least two promoters is described in the literature to mediate *Pax6* expression in different tissues \[[@r26],[@r27]\]. Thus, one promoter mediates expression in the brain, and differential *PAX6* transcription through alternate promoter usage could be involved in neural development \[[@r28]\].

The auditory fibers travel through the interhemispheric pathways, and it has been demonstrated that children with *PAX6* mutations and abnormalities of the interhemispheric pathways on MRI harbor reduced auditory capacities even in the presence of normal audiograms \[[@r10]\]. We did not observe any major clinical auditory deficits in any of the ten studied patients, although the three patients with available MRIs showed abnormal interhemispheric pathways. However we cannot conclude on the auditory status since we did not perform any specific tests, including the study of auditory-evoked potentials.

Mitchell et al. \[[@r13]\] published an MRI study of 24 aniridia patients with *PAX6* mutations and found absence of the pineal gland in 13/24 patients (54%). These authors concluded that this observation may be common in aniridia patients. Indeed, we have previously reported absence of the pineal gland in aniridia patients \[[@r29]\] as we do in the three patients of the present series in whom we performed MRI. As previously mentioned, sleep study was not performed and thus we could not assess the functional consequences of the absence of pineal glands. Mice homozygous for mutations in the *Pax6* gene harbor a wide variety of neurodevelopmental abnormalities, including absence of the corpus callosum and pineal gland \[[@r30],[@r31]\].

*PAX6* affects the development and function of the central nervous system and the eye as well as the pancreas and the hypothalamopituitary axis through the hypothalamus \[[@r3]\], which shares with the retina a common embryologic origin---the neural plate. Unfortunately, we were not able to perform electroretinography or endocrine testing to study the effect of the *PAX6* mutations on the retina and hypothalamopituitary axis.

Finally, WAGR syndrome (OMIM [194072](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=194072)), which includes Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation, is caused by either microscopic or submicroscopic deletion of chromosome 11p13-p12 in a region containing both the Wilms tumor 1, *WT1*gene and the *PAX6* genes. A contiguous syndrome, the WAGRO syndrome (OMIM [612469](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=612469)), includes the features of WAGR with obesity and is caused by a similar deletion that includes the Brain-derived neurotrophic factor, *BDNF* gene as well. Both syndromes were clinically excluded by normal kidney and urogenital ultrasonography performed on our patients.

In summary, we describe three mutations found in three families from northwestern Egypt, adding two novel mutations to the existing spectrum of *PAX6* mutations. Two of the three mutations are frameshifting small deletions and one is a previously described nonsense mutation. While the ten familial aniridia patients of this series harbored typical features of ocular-isolated aniridia, we observed a wide spectrum of MRI brain malformations, including absence of the pineal gland, hypogenesis of the corpus callosum with Probst bundles, and hypoplasia of the anterior or posterior commissure in patients not harboring major neurological development anomalies. Correlation between phenotype and genotype of *PAX6* mutations is still in its infancy in regard to brain malformations. The wide spectrum of *PAX6*-related anomalies and the fact that aniridia is frequently caused by *PAX6* mutations should prompt physicians facing aniridia to perform an examination of the central nervous system (at least with an MRI), an ultrasonography of the kidney and of the urinary pathways, a study of the kidney functions, and most importantly a complete assessment of the pituitary hormones and hypothalamic-releasing hormones.
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